Europe approves Seebri

The European Commission approved Seebri Breezhaler glycopyrronium bromide ( NVA237) from Novartis AG (NYSE:NVS; SIX:NOVN) as a once-daily, inhaled maintenance bronchodilator therapy for chronic obstru...